Name: Pfizer vaccine 85 percent effective after first dose, Israeli study finds
Brand: thehill.com
SKU: thehill-com-2476
Availability: OnlineOnly

critic

Pfizer vaccine 85 percent effective after first dose, Israeli study finds

preview

by - 02/19/21 8:50 AM ET✕The Pfizer COVID-19 vaccine is 85 percent effective 15-28 days after just one dose, according to a new Israeli study, helping bolster the case for possibly delaying the second dose of vaccine to cover more people.The study of health care workers at Sheba Medical Center in Israel, the journal The Lancet, found the vaccine was 85 percent effective in preventing symptomatic cases of COVID-19. When asymptomatic cases were included too, the figure was 75 percent.Those are promising results for just one dose of the vaccine. The Pfizer clinical trials were conducted with a two-dose regimen, which found 95 percent effectiveness.Some experts have been pushing for delaying the second dose in an effort to vaccinate more people faster. The United Kingdom has controversially adopted such a strategy.A limitation of the study, though, is that it does not determine how long the protection from just one dose will last.Some experts are also worried that providing a weaker vaccination of just one dose could allow dangerous variants of the virus to evolve to evade that lower level of protection.&nbsp;“Early reductions of COVID-19 rates provide support of delaying the second dose in countries facing vaccine shortages and scarce resources, so as to allow higher population coverage with a single dose,” the authors write in The Lancet. “Longer follow-up to assess long-term effectiveness of a single dose is needed to inform a second dose delay policy.”Anthony Fauci, the government’s top infectious disease expert, responded to the study at a White House press briefing Friday, saying he still thinks the U.S. should stick with a two-dose approach.Fauci&nbsp;raised the concerns that it is unclear from the study how long the one-dose protection will last, and noted that the immune response is much stronger after the second dose, which also provides more cushion if the new variants of the virus erode the vaccine’s protection somewhat.“The one thing we don’t know is how durable it is,” he said of one dose.“The second dose is ten times higher in the sense of level of neutralizing antibodies,” he added.—Updated at 12:48 p.m.✕✕× Close Ad

by - 02/19/21 8:50 AM ET✕The Pfizer COVID-19 vaccine is 85 percent effective 15-28 days after just one dose, according to a new Israeli study, helping bolster the case for possibly delaying the second dose of vaccine to cover more people.The study of health care workers at Sheba Medical Center in Israel, the journal The Lancet, found the vaccine was 85 percent effective in preventing symptomatic cases of COVID-19. When asymptomatic cases were included too, the figure was 75 percent.Those are promising results for just one dose of the vaccine. The Pfizer clinical trials were conducted with a...

public

Peter Sullivan

The Hill is the premier source for policy and political news. Follow for tweets on what's happening in Washington, breaking news and retweets of our reporters.

thehill.com

Credible

Speculation

Anecdotal Evidence

Generalization

Stacking the Deck

Appeal to Authority

Straw Man

Slippery Slope

Emotional Appeal

Red Herring

False Dilemma

Illogical

Moral Equivalency

Ad Hominem

Correlation w/o Causation

Semantics

Begging the Question

Faulty Analogy

Non Sequitur

Bandwagon

Dogmatism

Failing Occam's Razor

Biased

Pure Opinion

Hit Piece

Racial Bias

National Bias

Religious Bias

Financial Incentive

Political Agenda

Gender Bias

Misused Image/Video

Study Misinterpreted

Mistake

Misused Term

Science Misrepresented

Factual Error

Satire

Surface Level

Lack of Reliable Sources

Sensational

Not Credible

Investigative

Balanced

Well Sourced

Great Context

sports

entertainment

U.S.

international

business

technology

science

culture

politics

media

health

Pfizer vaccine 85 percent effective after first dose, Israeli study finds

No article scores yet.

CRITIC REVIEWS

PUBLIC REVIEWS